A couple of things I found interesting about what GC mentioned as distinguishing marks of AMBS's strategy: - Building a team of specialists who know how to take science and bring it to real world (market) results and not just how to make something look good in theory. - Building a portfolio of products each of which have multiple indications. This in contrast to a company that specializes and goes deep in just one thing.
As a result I am on the lookout for AMBS to continue to pursue acquisitions to broaden the portfolio of undervalued diamonds in the rough that AMBS can bring to market where others failed or stalled (like Eltoprazine and Lympro).
News 
Market Data 
Discover 
AI
